1642/JB

PATENT

Pragitioner's Docket No. MPI00-557P1RM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRIFFE application of:

Chiang, Lillian Wei-Ming, et al. (as amended)

Application No.:

10/047,855

Group No.: 1642

Filed:

January 15, 2002

Examiner: Laura B. Goddard

For:

NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

MAIL STOP PETITION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF AMENDMENT AND PETITION UNDER 37 C.F.R. 1.48(a) TO CORRECT INVENTORSHIP

- 1. Transmitted herewith for this application are:
 - a. This Transmittal of Amendment and Petition Under 37 C.F.R. 1.48(a) to Correct Inventorship (2 pages in duplicate);
 - b. Amendment and Petition under 37 C.F.R. 1.48(a) to Correct Inventorship (1 page);
 - c. Statements of Lack of Deceptive Intent under 37 C.F.R. 1.48(a) (2 pages);
 - d. Combined Declaration and Powers of Attorney of Lillian Wei-Ming Chiang, Andrew Wood, and Lorayne P. Jenkins (8 pages);
 - e. Consent of Assignee to Addition of Inventor under 37 C.F.R. 1.48(a) (1 page);
 - f. Copy of Notice of Recordation of Assignment Document, Recordation Form Cover Sheet, and executed Assignment (4 pages); and
 - g. Return receipt postcard.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

□ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

Date: ___March 30, 2006

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

2. Fee (37 C.F.R. Section 1.17(1)):

\$130.00

3. Payment of fee:

Charge Account No. 501668 the sum of \$130.00. A duplicate of this request is attached. If any additional fee is required, please charge Account No. 501668.

4. Correspondence Address

Direct all future correspondence to:

Customer Number 30405
OR
ellectual Property Departm

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

March 30, 2006

MILLENNIUM PHARMACEUTICALS, INC.

Tracy M. Sioussat

Attorney/Agent for Applicant

Reg. No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone: (617) 374-7679 Facsimile - (617) 551-8820

ractitioner's Docket No. MPI00-557P1RM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In reapplication of:

Chiang, Lillian Wei-Ming, et al. (as amended)

PADAPPlication No.:

10/047.855

Group No.: 1642

Filed:

January 15, 2002

Examiner: Laura B. Goddard

For:

NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

Mail Stop Petition Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND PETITION UNDER 37 C.F.R. § 1.48(a) TO CORRECT INVENTORSHIP

Applicant hereby petitions, pursuant to the provisions of 37 C.F.R. § 1.48(a), to correct the inventorship of the subject application to add Andrew Wood and Lorayne P. Jenkins as co-inventors.

Andrew Wood, of 2051 Leedoms Drive, Newton, Pennsylvania, and Lorayne P. Jenkins, of 7243 Elm Court, Monmouth Junction, JN 08852, are co-inventors of the invention being claimed in the subject application along with originally named co-inventor Lillian Wei-Ming Chiang.

Accordingly, upon grant of this petition, the persons named as the inventors of the subject application will be Lillian Wei-Ming Chiang, Andrew Wood, and Lorayne P. Jenkins.

04/05/2006 HDESTA1 00000078 501668 10047855 MILLENNIUM PHARMACEUTICALS, INC.

01 FC:1464

130.00 DA

Tracy M. Sioussat, Registration No. 50,609

40 Landsdowne Street Cambridge, MA 02139 Telephone: 617-374-7679 Facsimile 617-551-8820

Date: March 30, 2006

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

 \boxtimes deposited with the United States Postal Service in an envelope addressed to Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

X with sufficient postage as first class mail. as "Express Mail Post Office to Address"

Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: March 30, 2006

Sean Hunziker (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Attorney's Docket No. 35800/242056(5800-190)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Chiang et al.

Confirmation No.: 5102

Appl. No.: 10/047,855

Group Art Unit: 1645

Filed:

Examiner:

Not Assigned

For:

January 15, 2002

NARC10 AND NARC16 PROGRAMMED CELL-DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

Commissioner for Patents Washington, DC 20231

STATEMENT OF LACK OF DECEPTIVE INTENT UNDER 37 CFR 1.48(a)

Sir:

I, Andrew Wood, declare that:

- I am an inventor of the invention disclosed in the above-identified patent 1. application.
- Due to an error, my name was not included as an inventor when the application 2. was filed.
- 3. Error in the exclusion of my name on the above-identified patent application was made without any deceptive intent on my part.

Signature:

ttorney's Docket No. 35800/242056(5800-190)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Chiang et al. 10/047,855

Confirmation No.: 5102

Group Art Unit: 1645

Filed:

January 15, 2002

Examiner:

Not Assigned

For:

NARC10 AND NARC16 PROGRAMMED CELL-DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

Commissioner for Patents Washington, DC 20231

STATEMENT OF LACK OF DECEPTIVE INTENT UNDER 37 CFR 1.48(a)

Sir:

I, Lorayne P. Jenkins, declare that:

- I am an inventor of the invention disclosed in the above-identified patent 1. application.
- 2. Due to an error, my name was not included as an inventor when the application was filed.
- 3. Error in the exclusion of my name on the above-identified patent application was made without any deceptive intent on my part.

Intens Date: 8/22/02

COMBINED DECLARATION AND POWER OF ATTORNEY

ÖRIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL, CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a(n) nonprovisional application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED MOLECULES AND USES THEREOF

SPECIFICATION IDENTIFICATION

The specification was filed on January 15, 2002, as Serial No. 10/047,855.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56, and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent.

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S) UNDER 35 U.S.C. SECTION 119 or 35 U.S.C. SECTION 365

I hereby claim the benefit, under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or Title 35, United States Code, Section

Practitioner's Docket No. MPI00-557P1RM

365(a) of any PCT international application which designated at least one country other than the United States of America, and have also identified below, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

			OVISIONAL APPLI ER 35 U.S.C. SECTI	
FOREIGN APPLICATION NO.	FILING DATE	Country	Priority Claimed	Status
		/		

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NO.	FILING DATE		
60/262,306	January 16, 2001		Abandoned

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S) UNDER 35 U.S.C. SECTION 120

I hereby claim the benefit, under Title 35, United States Code, Section 120, of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information that occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

Practitioner's Docket No. MPI00-557P1RM

	APPLICATIONS OR I NG THE U.S. FOR BE			
U.S. APPLICA	ATIONS	Status	•	
U.S. APPLICATIONS	U.S. FILING DATE	Patented	Pending	Abandoned
PCT APPLICATION I U.S.	DESIGNATING THE			
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NOS. ASSIGNED (IF ANY)		

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) (PTO Customer Number 30405) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)	REGISTRATION NUMBER(S)
Scott A. Brown	32,724
Ian R. Silverman	37,443
Jean M. Silveri	39,030
Tracy M. Sioussat	50,609
Janice M. Klunder	41,121
Karoline K.M. Shair	44,332
Mario Cloutier	57,225

Practitioner's Docket No. MPI00-557P1RM	· •
SEND CORRESPONDENCE TO	DIRECT TELEPHONE CALLS TO:
Jean M. Silveri Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, MA 02139 DIRECT FACSIMILE CORRESPONDENCE Jean M. Silveri	<u>Jean M. Silveri</u> 617 679-7336 TO:
617-551-8820	
D	ECLARATION
statements made on information and belief ar made with the knowledge that willful false	made herein of my own knowledge are true and that all the believed to be true; and further that these statements were statements and the like so made are punishable by fine or Title 18 of the United States Code, and that such willful false pplication or any patent issued thereon.
S	IGNATURE(S)

SIGNATURE(S)
Lillian Wei Ming Chief
Lillian Wei-Ming Chiang
Inventor's signature Mula
Date 3//5/06
Residence Princeton, New Jersey 08540
Post Office Address 12 Boudinot Street., Princeton, New Jersey 08540
Country of Citizenship United States
•
Andrew Wood
Inventor's signature
Date
Residence Newton, Pennsylvania 18940
Post Office Address 2051 Leedoms Drive, Newton, Pennsylvania 18940
Country of Citizenship United Kingdom
Lorayne P. Jenkins
Inventor's signature
Date
Residence Monmouth Junction, New Jersey 08852
Post Office Address 4243 Elm Court, Monmouth Junction, New Jersey
08852
Country of Citizenship United States



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NARC10 AND NARC16 PROGRAMMED CELL DEATH-ASSOCIATED MOLECULES AND USES THEREOF,

the specification of which is attached hereto	
OR	
was filed on January 15, 2002 as United States Application N	No. 10/047,855.
I hereby state that I have reviewed and understand the contents of specification, including the claims, as amended by any amendments	

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

			Yes No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			Yes No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			Yes No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

60/262,306	01/16/ 2001
Application Number	Filing Date (MM/DD/YYYY)
Application Number	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

Application No.	Filing Date	Status Patented/Pending/Abandoned
Application. No.	Filing Date	Status Patented/Pending/Abandoned
Application No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following practitioners:

Scott A. Brown, Reg. No. 32,724
Jean M. Silveri, Reg. No. 39,030
Susan M. Perkins, Reg. No. 36,405
Theodore Allen, Reg. No. 41,578
Kerri Pollard-Schray, Reg. No. 47,066
Steven A. Bossone, Reg. No. 51,196
Tracy Sioussat, Reg. No. 50,609
Carmen Pili Ekstrom, Reg. No. 34,981
Ian R. Silverman, Reg. No. 37,443

Elizabeth M. Barnhard., Reg. No. 31,088 Egon E. Berg, Reg. No. 21,117 Bill T. Brazil, Reg. No. 50,733 William H. Calnan, Reg. No. 29,520 Diana M. Collazo, Reg. No. 46,635 Bruce Eisen, Reg. No. 22,847 Alan M. Gordon, Reg. No. 30,637 Barbara A. Gyure, Reg. No. 34,641 Elizabeth A. Hurley, Reg. No. 41,859 David A. Manspeizer, Reg. No. 37,540 Gale F. Matthews, Reg. No. 32,269 Mary Andrea Ryan, Reg. No. 28,469 Fariba Shoarinejad, Reg. No. 48,182 Albert Ubieta, Reg. No. 43,212 Darryl L. Webster, Reg. No. 34,276

and, I also appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 00826

Direct telephone calls to:

W. Murray Spruill Registration No. 32,943

Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260

Full name of (first/sole) inventor: Lillian Wei-Ming Chiang Inventor's Signature: Date: Residence: Edison, NJ Citizenship: United States of America Mailing Address: 174 Tiffany Drive Edison, NJ 08820 Andrew Wood Full name of second inventor: Inventor's Signature: Date: OS Residence: Newton, PA Citizenship: Great Britain Mailing Address: 2051 Leedoms Drive Newton, PA 18940 Full name of third inventor: Lorayne P. Jenkins Inventor's Signature: Residence: Citizenship: United States of America Mailing Address: 7243 Elm Court Monmouth Junction, NJ 08852

Practitioner's Docket No. MPI00-557P1RM

APR 9 4 2006 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Chiang, Lillian Wei-Ming, et al. (as amended)

Application No.:

10/047,855

Group No.: 1642

Filed:

January 15, 2002

Examiner: Laura B. Goddard

For: NARC10 AN

NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED

MOLECULES AND USES THEREOF

MAIL STOP PETITION Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

CONSENT OF ASSIGNEE TO ADDITION OF INVENTOR UNDER 37 CFR § 1.48(a)

Millennium Pharmaceuticals, Inc., located at 40 Landsdowne Street, Cambridge, Massachusetts, assignee of the entire right, title, and interest in and to U.S. Patent Application Serial No. 10/047855, filed on January 15, 2002 (35 USC 371 date), hereby consents to the correction of inventorship requested in the Petition Under 37 CFR § 1.48(a) filed herewith. The undersigned is empowered to sign this statement on behalf of Millennium Pharmaceuticals, Inc.

Ownership by the Assignee is established by an Assignment from Lillian Wei-Ming Chiang, recorded in the U.S. Patent and Trademark Office on June 4, 2002, at Reel 012959, Frame 0349. A copy of the Notice of Recordation of the Assignment, Recordation Cover Sheet, and executed Assignment is attached.

Respectfully Submitted,

MILLENNIUM PHARMACEUTICALS, INC.

Date: March 30, 2006

By:

Scott A. Brown

Deputy General Counsel



AUG 1 212002

KLC

AUGUST 07, 2002

PTAS

Chief Information Officer Washington, DC 20231 www.uspto.gov

ALSTON & BIRD LLP KATHRYN L. COULTER BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000 CHARLOTTE, NC 28280-4000



UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/04/2002

REEL/FRAME: 012959/0349

NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

CHIANG, LILLIAN WEI-MING

DOC DATE: 05/03/2002

ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 10047855

PATENT NUMBER:

FILING DATE: 01/15/2002

ISSUE DATE:

MARY BENTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

ALSTON & BIRD

RTA

RECEIVED

K13 (Da Wa



ASSIG

C.Z-11-2002

COVER SHEET Patents Only

	te Honorable Commissi e record the attached on 102118636	Attorney Dkt. No.: 35800/242056(5800-190)
1.	Name of conveying party(ies):	2. Name and address of receiving party(ies):
٨	E Lillian Wei-Ming Chiang 4 2006 onal name (s) of conveying party(ies) attached? Yes No No	Millennium Pharmaceuticals, Inc. 75 Sidney Street Cambridge, MA 02139 TINANCE SECTION OFFICE OF PUBLIC RECORD
3.	Nature of conveyance: Assignment Merger Security Agreement Change of Name Other Execution Date: May 3, 2002	SECTION SECORD Additional name(s) & address(es) attached? Yes \(\square\) No \(\square\)
4.	Application No. 10/047,855; Filed January 15, 2002	Patent No.
	If this document is being filed together with a new applicate: Additional numbers attached? Yes \(\sigma\) No \(\sigma\)	cation, the execution date of the application
5.	Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved:1
	ALSTON & BIRD LLP Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000	
10/2002 1	DBYRNE 00000075 10047855 / 40.00 gp	7. Total fee (37 CFR 3.41) \$40.00 Enclosed Authorized to be charged to deposit account
FC=581	40.00 WP	8. Deposit account number: 16-0605
	Statement and signature: To the best of my knowledge and belopy of the original document. Kathum L Wille	SE THIS SPACE lief, the foregoing information is true and correct and any attached copy is a 5/15/2002
Name	of Person Signing: Kathryn L. Coulter Reg. No. 45,889 Total number of pages including co	Date over sheet, attachments, and document: 3

01

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor has sold and assigned, and by these presents hereby sells and assigns, unto

Millennium Pharmaceuticals, Inc. 75 Sidney Street Cambridge, MA 02139

its successors and assigns, the entire right, title and interest, so far as concerns the United States and the Territories and Possessions thereof and all foreign countries in and to the invention in "NARC 10 AND NARC 16, PROGRAMMED CELL DEATH-ASSOCIATED MOLECULES AND USES THEREOF"

as set forth in this United States Patent Application

executed concurrently herewith
executed on
Application No. 10/047,855; filed January 15, 2002
Application claims priority from Application No. 60/262,306, filed January 16, 2001, all applications listed above being hereinafter referred to as the "application(s)";

said application for United States Letters Patent, including all divisional, renewal, substitute, continuation, non-provisionals, continuation-in-parts, and Convention applications based in whole or in part upon said inventions or upon said applications, and any and all Letters Patent and reissues, reexaminations, and extensions of Letters Patent granted for said inventions or upon said applications and every priority right that is or may be predicated upon or arise from said inventions, said applications, and said Letters Patent; said Assignee being hereby authorized to file patent applications in any or all countries on any or all said inventions in the name of the undersigned or in the name of said Assignee or otherwise as said Assignee may deem advisable, under the International Convention or otherwise; the Commissioner of Patents and Trademarks of the United States of America being hereby authorized to issue or transfer all said Letters Patent to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right theretofore given, and that the undersigned will do all acts reasonably serving to ensure that the said inventions, patent applications and Letters Patent shall be held and enjoyed by said Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to said Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, declarations, and lawful affidavits in form and substance which may be requested by said Assignee, to furnish said Assignee with all facts relating to said inventions or the history thereof and any and all documents, photographs,

models, samples or other physical exhibits which may embody said inventions, and to testify in any proceedings relating to said inventions, patent applications, and/or Letters Patent.

The undersigned hereby grant(s) an authorized representative of Assignee the power to insert in this Assignment any further identification that may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

Date 5/3/02 Lillian Wei-Ming Chiang
State of New Tersey
State of New Tersury County of Middle sex
I, <u>Kathy Kerrigan</u> , a Notary Public for said County and State, do hereby certify that Lillian Wei Ming Chiang personally appeared before me this day and acknowledged the due execution of the foregoing instrument.
Witness my hand and official seal, this the
(Official Seal) **All Hybrids** (Notary Public**
My commission expires KATHY KERSEAN NOTARY PUBLIC OF NEW EXCENT